Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, and Attending Physician, Pediatric Emergency Medicine, Nemours/Alfred I duPont ...
New RSV shots and monoclonals cut infant hospitalizations up to 85%, with strong real‑world safety—learn what efficacy vs effectiveness really means. This episode provides a clear-eyed analysis of ...
A titanium-based lithium coin-cell battery reduced visible esophageal tissue injury compared with traditional batteries in a porcine model. The protective battery still generated alkaline hydroxide, ...
The FDA approved the first generic version of rifapentine tablets, previously marketed as Priftin. Rifapentine is indicated for active pulmonary tuberculosis in patients aged 12 years and older and ...
The PANDAS/PANS questionnaire is based on symptoms and comorbidities described in the literature and is a self-report completed by parents of children younger than 18. "Bottom line, previous surgery ...
FDA designations for investigational GEn-1123 may support development in Duchenne muscular dystrophy, but clinical data remain limited. The FDA has granted orphan drug designation and rare pediatric ...
The FDA has approved bemotrizinol as GRASE for sunscreen use at up to 6%, the first new OTC sunscreen active ingredient in approximately 20 years, cleared for adults and children 6 months and older.
Any infant who consumed Nara Organics Whole Milk Organic Powdered Infant Formula and presents with constipation, poor feeding, hypotonia, loss of head control, or facial weakness should be evaluated ...
The FDA's Warning Letter identifies the SNOO X-Small and X-Large sleep sacks as unauthorized modifications to an FDA-cleared device; clinicians should caution families to discontinue use of these ...
In each of 5 influenza seasons from 2016 to 2023, children aged 2 to 5 years with fall birthdays, who were more likely to be vaccinated due to well-child visit timing, had consistently lower rates of ...
Vertex reported phase 3 ALYFTREK data in children aged 2 to 5 years with cystic fibrosis and responsive CFTR genotypes. “The data we’re presenting today bring us to the cusp of our 25-year mission to ...
The FDA approved lebrikizumab-lbkz (EBGLYSS) for a maintenance dosing regimen of 250 mg every 8 weeks in adults and adolescents ≥12 years and ≥40 kg with moderate-to-severe atopic dermatitis, allowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results